Itrm fda report is out on the 27th of October. Should I purchase stock now.

**Consider the following points before making a decision on whether to purchase ITRM stock now**: 1. **FDA Decision Imminent**: The FDA's decision on the approval of oral sulopenem for the treatment of uUTIs in adult women is expected by the PDUFA goal date of October 25, 2024. This timing is critical for Iterum Therapeutics. 2. **Potential Approval Impact**: If approved, sulopenem would become the first oral penem to be approved in the United States, which could be a significant milestone for the company. 3. **Recent News and Market Sentiment**: Recent updates from the FDA advisory committee meeting have been positive, with oral sulopenem acknowledged as an important treatment option. However, the stock has experienced a significant drop, 51.8% so far this year, which may reflect market sentiment. 4. **Financial Estimates and Earnings**: The estimated EPS for 2024 Q4 is -$0.22, and the estimated revenue for the same period is not available. The upcoming earnings report on October 27th will provide clarity on the company's financial health and the potential impact of the FDA decision. 5. **Strategic Position and Future Prospects**: Iterum Therapeutics is focused on developing next-generation oral antibiotics, and the approval of sulopenem could be a pivotal point for the company, potentially opening up new markets and opportunities. 6. **Market Position and Competition**: The company faces competition from other pharmaceutical companies and the potential for high risk associated with off-label use of sulopenem, which could affect its market position. **In conclusion, while there is potential for a positive outcome with the FDA decision, the recent news and market sentiment suggest caution. It is recommended to wait for the FDA decision and the upcoming earnings report on October 27th to assess the company's financial health and the true impact of the FDA decision before making a purchase decision.**